Latest arGEN-X Stories
BREDA, the Netherlands, June 4, 2014 /PRNewswire/ -- SIGNIFICANTLY EXPANDED RELATIONSHIP CREATED ON BACK OF COLLABORATION SUCCESS arGEN-X, a clinical-stage
BREDA, The Netherlands and GHENT, Belgium, May 29, 2014 /PRNewswire/ -- arGEN-X will present full results from the dose-escalation part of a Phase 1 study of ARGX-110,
BREDA, The Netherlands, May 28, 2014 /PRNewswire/ -- arGEN-X, a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies
- Monstrous in size or character; huge; prodigious; monstrously perverse, savage, cruel, etc.